T-rapamycin cell donor lymphocyte infusions (Lymphoma), National Cancer Institute

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameT-rapamycin cell donor lymphocyte infusions (Lymphoma), National Cancer Institute
Drug Alias NameT-rapamycin cell donor lymphocyte infusions (Lymphoma)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionUpdating
TargetsNot applicable
Therapy Area/IndicationsLymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNational Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Cancer Center
Active IndicationsN/A
Inactive IndicationsLymphoma

Other Information

ATC CodeN/A
Related LinksN/A